Skip to main content

Table 1 Baseline demographics and clinical characteristics of pediatric subjects in the mOIT, rush mOIT, and control groups

From: Multiple-allergen oral immunotherapy improves quality of life in caregivers of food-allergic pediatric subjects

 

mOIT*

Rush mOIT*

Control

Number of subjects

29

11

10

Median age in years (range)

8 (4 – 13)

7 (4 – 16)

8 (4–14)

Male

18 (62%)

8 (72%)

5 (50%)

Coexisting atopic disease

 

 Atopic dermatitis

20 (69%)

5 (45%)

5 (50%)

 Allergic rhinitis

15 (52%)

6 (55%)

6 (60%)

 Asthma

21 (72%)

8 (73%)

7 (70%)

Food allergies meeting criteria for inclusion on DBPCFC**

 Peanut

20 (69%)

7 (64%)

7 (70%)

 Walnut

11 (38%)

5 (45%)

4 (40%)

 Cashew

9 (31%)

6 (55%)

3 (30%)

 Pecan

8 (28%)

5 (45%)

3 (30%)

 Milk

8 (28%)

3 (27%)

2 (20%)

 Egg

4 (14%)

4 (36%)

3 (30%)

 Sesame

4 (14%)

0 (0%)

2 (20%)

 Almond

3 (10%)

3 (27%)

2 (20%)

 Hazelnut

2 (7%)

1 (9%)

2 (20%)

Average number of desensitized foods

 

3

4

n/a

Highest baseline food allergy test (median and range)

 SPT in mm

13.5 (7–25.5)

10.5 (7–29.5)

10.5 (7–30.5)

 Specific IgE in ku/L

82.5 (2.95- > 100)

36.4 (2- > 100)

61 (3.25- > 100)

 Lowest amount triggering reaction in DBPCFC in mg protein

32.7 (0.1-182.7)

32.7 (0.1-182.7)

32.7 (0.1-182.7)

  1. *OIT = oral immunotherapy. **DBPCFC = double blind placebo controlled food challenge.